Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.

Full results of the boceprevir HCV SPRINT-1 study and early phase clinical results with SCH 900518 are being submitted for presentation at a future medical meeting.

About the Boceprevir HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). SVR rates are not yet available for Part II of this study evaluating boceprevir with low-dose REBETOL (n=59) compared to contemporaneous control (n=16) as described above.

About Boceprevir Phase III Studies

Schering-Plough is conducting two large ongoing pivotal Phase III studies of boceprevir in patients chronically infected with HCV genotype 1. One study is in treatment-naive patients and the other in patients who failed prior treatment (relapsers and nonresponders). The two randomized, double-blind, placebo-controlled studies evaluate the efficacy of boceprevir in combination with PEGINTRON and REBETOL compared to standard of care
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented at ... a therapy being developed by Hera Therapeutics Inc. combats three ... percent of all cervical cancer. When tested in ... HPV-16, HPV-18 and HPV-11 cells, according to Louise T. ... presented the findings at the Seattle ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... Inc. (NYSE: HSP ), a leading global specialty ... will present at the Morgan Stanley Global Healthcare Conference on ... presentation is scheduled to begin at 8:35 a.m. Eastern time ... all interested parties through a live audiocast accessible via the ...
... Wright Therapy Products, Inc. announced today that ... Executive Officer of the company.  The company, based ... devices targeted for the treatment of lymphedema, venous ... Wright Therapy after holding senior financial and sales ...
Cached Medicine Technology:Industry Leaders Hinson and Friel Join Wright Therapy Products 2
(Date:8/23/2014)... 2014 Dealing with a drug or alcohol ... the addict is a child. Adolescent addiction has been an ... time, but a new helpline is now providing a valuable ... to find a real addiction recovery center. , The Troubled ... impact in the community. By calling (404) 975-2762, parents and ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 Search ... on the first page of search engines and ... SEO Hosting has recently compared many Linux hosting ... and Bluehost are the most recommended Linux hosting ... Australia and Europe to buy high quality Linux ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online Health ... Plans. , According to Zane Benefits, employers are adopting ... the cost of healthcare without reducing coverage for employees. ... can be confusing. , The new guide contains a ... types of ABHPs. It also explains the similarities, ...
(Date:8/22/2014)... 23, 2014 This report studies ... Liquid Handling Systems), Consumables (Tubes), Kits (Isolation, Purification), ... Diagnostics) - Global Forecast to 2018" This market ... is poised to grow at a CAGR of ... million by 2018. , Browse 98 market data ...
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and ... wedding gowns . In addition to this, the company’s ... are provided with low shipping fees. , He ... new wedding gowns. In our online store, there are ... choose from. What’s more, all of them are extremely ...
Breaking Medicine News(10 mins):Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2
... harbor profound misperceptions about the effects ... designed to help them quit, PITTSBURGH, Nov. 13 ... dangers of smoking over the past 40 years, a ... GlaxoSmithKline,Consumer Healthcare, an industry leader in smoking cessation, indicates,major ...
... Disease & Kennel Cough: Serious, But Avoidable; ... Reputable Pet Sitter, BERKELEY, Calif., Nov. 13 With ... reports regarding the highly,contagious and potentially deadly strains of canine ... cough virus -- have many dog,owners worried. So, what,s a ...
... is the only way,to describe the unsolicited testimonial received this month by ... Because of your service we were there within about ... is already home as of yesterday evening. Your service ... never work for her because when she has an ...
... Inc., a subsidiary of Natural Nutrition Inc. ... made another major,breakthrough in the international market ... Panama. InterACTIVE Nutrition brand high energy protein,products ... department in Panama.,This is a significant achievement, ...
... Today; ... in the United States, LYON, France, November 13 ... it has,signed an exclusive global collaboration agreement with Acambis plc, ... help fight against,this serious, life-altering and potentially fatal disease. Scientists,believe ...
... carbohydrates may help stunt the growth of prostate tumors, according ... The study, in mice, suggests that a reduction in insulin ... , This study showed that cutting carbohydrates may slow tumor ... urologist at Duke University Medical Center and lead researcher on ...
Cached Medicine News:Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 2Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 3Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 4Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 5Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 6Health News:Safeguard Your Pet From Seasonal Ailments 2Health News:Safeguard Your Pet From Seasonal Ailments 3Health News:Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service 2Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Panama 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:A low-carb diet may stunt prostate tumor growth 2
... The Estriol (unconjugated) enzyme immunoassay (EIA) test ... in vitro,determination of unconjugated estriol in human ... The Estriol (unconjugated) procedure is an enzyme ... competitive binding. In this procedure, estriol is ...
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... based on the competition principle and the ... in the sample and a fixed amount ... for the,binding sites of a polyclonal Estradiol ... hours incubation the microtiterplate is,washed to stop ...
... the most important androgen secreted into the ... the Leydig cells of the testes; in ... derived from,peripheral conversion of androstenedione, ca. 25% ... the adrenal glands. The Testosterone ELISA KIT ...
Medicine Products: